Budesonide-Formoterol for COPD Management

Guideline Recommendations and Efficacy

• The American College of Chest Physicians and Canadian Thoracic Society guidelines strongly recommend maintenance combination inhaled corticosteroid/long-acting β-agonist therapy, such as budesonide-formoterol, compared with long-acting β-agonist monotherapy to prevent acute exacerbations in patients with stable moderate, severe, and very severe COPD (Grade 1C) 2, 3
• Combination ICS/LABA therapy is recommended over ICS monotherapy for preventing acute exacerbations of COPD (Grade 1B) 4, 2
• The 2023 Canadian Thoracic Society guideline notes that budesonide/formoterol has demonstrated efficacy in reducing exacerbation rates in high-risk COPD patients 1
• The benefit-risk ratio favors combination therapy with a number needed to treat of 4 patients for 1 year to prevent one moderate to severe exacerbation versus a number needed to harm of 33 patients for 1 year to cause one pneumonia 1

Patient Assessment and Therapy Consideration

• Budesonide-formoterol is particularly beneficial for patients with moderate to severe COPD (FEV1 <60% predicted) and a history of exacerbations 1, 2
• Consider budesonide-formoterol as maintenance therapy when patients have significant symptoms despite regular therapy with long-acting bronchodilators or have experienced repeated exacerbations 6, 4, 1

Safety and Monitoring

• Monitor for signs of pneumonia, especially in severe COPD, as the pneumonia risk should be considered with budesonide-formoterol therapy 1
• Be aware of other potential side effects such as oral candidiasis and dysphonia 4